May 17, 2023



Dear Fabry community,

It is with great pleasure that we announce the US Food and Drug Administration approval of a new treatment for adults with Fabry disease.

This approval is an important milestone in providing a new treatment for Fabry disease and would not have been possible without your dedication, commitment, and participation in the clinical trials. On behalf of Chiesi Global Rare Diseases, I want to express our heartfelt gratitude to you for playing a part in making this regulatory approval a reality.

We are proud to bring this new treatment to market but recognize that the journey to support people living with Fabry disease does not end here. We understand that treatment is only a part of the whole, so Chiesi provides a range of support, education, and advocacy services for people living with Fabry disease and their families. This includes Chiesi Total CareSM patient support services, as well as Fabry resources available at <u>chiesirarediseases.com</u>. You can also reach out to Chiesi Global Rare Diseases Patient Advocacy wia email: <u>grd.PatientAdvocacy@chiesi.com</u>.

We reached this important milestone thanks to you, and we will partner with the Fabry community and patient advocacy organizations to continue to develop programs and services. We are dedicated to ensuring that people impacted by Fabry disease, their care partners, and healthcare providers have access to the resources they need.

We invite you to watch a short video featuring Jack Johnson of the Fabry Support & Information Group; Jerry Walter of the National Fabry Disease Foundation; Stuart Siedman, Global Head of Patient Advocacy; and myself, Giacomo Chiesi, Head of Chiesi Global Rare Diseases. In the video, we discuss the importance of this approval and our ongoing commitment to the Fabry disease community. You can access the video through the link <u>https://youtu.be/EMtkci71v-E</u> or QR code provided below.

Thanks once again to you, the patient community, as well as to healthcare providers and the patient advocacy community, for your ongoing support and collaboration. Together, we can work to build a brighter future for everyone affected by Fabry disease.

Sincerely yours,

- Chip

Giacomo Chiesi Head of Global Rare Diseases Chiesi Group



Watch the video

©Chiesi USA, Inc. 2023. All rights reserved. Chiesi Total Care[™] is a service mark of CHIESI FARMACEUTICI S.p.A. PP-EF-0319 V1.0